Systems biology: A therapeutic target for tumor therapy

Cancer Microenvironment

Volumn 1, Issue 1, 2008, Pages 159-170

  Reichle, Albrecht ^a   Vogt, Thomas ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

COX 2 inhibitor; Dexamethasone; Interferon alpha; Metronomic low dose chemotherapy; Pioglitazone; PPARs; Systems biology; Transcription factors; Tumor microenvironment

Indexed keywords

ALPHA INTERFERON; C REACTIVE PROTEIN; CAPECITABINE; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; ETORICOXIB; GLUCOCORTICOID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; ROFECOXIB; TROFOSFAMIDE;

ANGIOSARCOMA; ARTICLE; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CONTROLLED STUDY; CUSHING SYNDROME; DEPRESSION; DRUG MEGADOSE; DRUG SAFETY; EDEMA; ELECTROCORTICOGRAPHY; HAND FOOT SYNDROME; HISTIOCYTOSIS X; HUMAN; KAPOSI SARCOMA; KIDNEY CARCINOMA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL;

EID: 58649102891     PISSN: 18752292     EISSN: 18752284     Source Type: Journal    
DOI: 10.1007/s12307-008-0012-5     Document Type: Article

References (51)

1. J Galon A Costes F Sanchez-Cabo 2006 Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science 313 1960 1964
2. HF Dvorak 1986 Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing N Engl J Med 315 1650 1659
3. F Balkwill LM Coussens 2004 Cancer: an inflammatory link Nature 431 405 406
4. MC Brahimi-Horn J Chiche J Pouyssegur 2007 Hypoxia signalling controls metabolic demand Curr Opin Cell Biol 19 223 229
5. HF Dvorak 1987 Thrombosis and cancer Hum Pathol 18 275 284
6. MM Mueller NE Fusenig 2004 Friends or foes - bipolar effects of the tumour stroma in cancer Nat Rev Cancer 4 839 849
7. LS Angelo R Kurzrock 2007 Vascular endothelial growth factor and its relationship to inflammatory mediators Clin Cancer Res 13 2825 2830
8. T Vogt C Hafner K Bross 2003 Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors Cancer 98 2251 2256
9. A Reichle K Bross T Vogt 2004 Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma Cancer 101 2247 2256
10. Reichle A, Klebl F, Bross K et al (2004) Pioglitazone and Rofecoxib combined with angiostatically scheduled capecitabine in far-advanced hepatobiliary carcinoma. Medimond S r l, pp. 87-98
11. A Reichle T Vogt L Kunz-Schughart 2005 Anti-inflammatory and angiostatic therapy in chemorefractory multisystem Langerhans' cell histiocytosis of adults Br J Haematol 128 730 732
12. A Reichle J Grassinger K Bross 2006 C-reactive Protein in patients with metastatic clear cell renal carcinoma: an important biomarker for tumor-associated inflammation Biomarker Insights 2 87 98
13. A Reichle T Vogt B Coras 2007 Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial Melanoma Res 17 360 364
14. Reichle A, Walter B, Berand A et al (2007) Induction of complete remission in metastatic hormone-refractory prostate cancer: a combined anti-inflammatory therapy approach. [abstract]. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings, vol. 25, no. 185
15. B Coras C Hafner A Reichle 2004 Antiangiogenic therapy with pioglitazone, rofecoxib, and trofosfamide in a patient with endemic kaposi sarcoma Arch Dermatol 140 1504 1507
16. A Kapainen MW Kieran S Huang 2007 PPARalpha deficiency in inflammatory cells suppresses tumor growth PLoS One 2 260e
17. C Hafner A Reichle T Vogt 2005 New indications for established drugs: combined tumor-stroma-targeted cancer therapy with PPARgamma agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapy Curr Cancer Drug Targets 5 393 419
18. Hafner C, Vogt T, Reichle A (2007) Conventional therapeutics with antiangiogenic activity. In: Davis DW, Herbst RS, Abbruzzese JL (eds) Antiangiogenic cancer therapy. CRC, Boca Raton, FL, pp 301-327
19. JY Lio D Ghelani S Yeh 2007 Non-steroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3epsilon Cancer Res 67 3185 3191
20. U Emmenegger Y Shaked S Maus 2007 Pharmacodynamic and pharmacokinetic studies of low-dose metronomic cyclophosphamide in mice Mol Cancer Ther 6 2280 2289
21. S Ogawa J Lozach C Benner 2005 Molecular determinants of crosstalk between nuclear receptors and toll-like receptors Cell 122 707 721
22. D Wang H Wang Y Guo 2006 Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression Proc Natl Acad Sci USA 103 19069 19074
23. KC Leung 2004 Regulation of cytokine receptor signaling by nuclear hormone receptors: a new paradigm for receptor interaction DNA Cell Biol 23 463 474
24. F Akbiyik DM Ray KF Gettings 2004 Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes Blood 104 1361 1368
25. LM Glode A Barqawi F Crighton 2003 Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma Cancer 98 1643 1648
26. IF Tannock R de Wit WR Berry 2004 Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 1502 1512
27. MR Middleton JJ Grob N Aaronson 2000 Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma J Clin Oncol 18 158 166
28. RJ Motzer TE Hutson P Tomczak 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115 124
29. T Vogt B Coras C Hafner M Landthaler 2006 Antiangiogenic therapy in metastatic prostate carcinoma complicated by cutaneous lupus erythematodes Lancet Oncol 7 695 697
30. K Plikat A Reichle MW Elmlinger 2003 Hypoglycemia associated with the production of insulin-like growth factor (IGF)-II by a hemangiopericytoma Dtsch Med Wochenschr 128 257 260
31. PA McArdle K Mir AS Almushatat 2006 Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer Urol Int 77 127 129
32. K Lundholm J Gelin A Hyltander 1994 Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors Cancer Res 54 5602 5606
33. R Morant J Bernhard D Dietrich 2004 Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial Br J Cancer 90 1312 1317
34. JA Storlie JC Buckner GA Wiseman 1995 Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma Cancer 76 96 100
35. F Porzsolt D Messerer R Hautmann 1998 Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate. A randomized multicenter trial J Cancer Res Clin Oncol 114 95 100
36. G Debrock V Vanhentenrijk R Sciot 2003 A phase II trial with rosiglitazone in liposarcoma patients Br J Cancer 89 1409 1412
37. R Buckstein RS Kerbel Y Shaked 2006 High-dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma Clin Cancer Res 12 5190 5198
38. HG Kopp L Kanz JT Hartmann 2006 Complete remission of relapsing high-grade angiosarcoma with single-agent metronomic trofosfamide Anticancer Drugs 17 997 998
39. MF McCarty J Barroso-Aranda F Contreras 2008 PPARgamma agonists can be expected to potentiate the efficacy of metronomic chemotherapy through CD36 up-regulation Med Hypotheses 70 419 23
40. WR Loewenstein Y Kanno 1966 Intercellular communication and the control of growth: lack of communication between cancer cells Nature 209 1248 1249
41. MH Tai CC Chang M Kiupel 2005 Oct-4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis Carcinogenesis 26 495 502
42. JD Webster V Yuzbasiyan-Gurkan JE Trosko 2007 Expression of the embryonic transcription factor Oct4 in canine neoplasms: a potential marker for stem cell subpopulations in neoplasis Vet Pathol 44 893 900
43. Trosko JE, Tai MH (2006) Adult stem cell theory of the multi-stage, multi-mechanism theory of carcinogenesis: role of inflammation on the promotion of initiated cells. In: Dittmar T, Zaenker KS, Schmidt A (eds) Infections and inflammation: impacts on oncogenesis. (Contributions to Microbiology, Vol. 13. Infection and inflammation: impacts on oncogenesis). S. Karger AG, Switzerland, pp 45-65
44. JE Trosko 2003 The role of stem cells and gap junctional intercellular communication in carcinogenesis J Biochem Mol Biol 36 43 48
45. T Ogawa T Hayashi M Tokunou 2005 Suberoylanilide hydroxamic acid enhances gap junctional intercellular communication via acetylation of histone containing connexin43 gene locus Cancer Res 65 9771 9778
46. RJ Ruch BV Madhukar JE Trosko 1993 Reversal of ras-induced inhibition of gap junctional intercellular communication, transformation, and tumorigenesis by lovastatin Mol Carcinog 7 50 59
47. JE Trosko RJ Ruch 2002 Gap junctions as therapeutic targets Current Drug Targets 3 465 482
48. JE Trosko 2007 Gap junction intercellular communication as a 'Biological Rosetta Stone' in understanding, in a systems manner, stem cell behavior, mechanisms of epigenetic toxicology, chemoprevention and chemotherapy J Membr Biol 218 93 100
49. G Roche-Nagle EM Connolly M Eng 2004 Antimetastatic activity of a cyclooxygenase-2 inhibitor Br J Cancer 91 359 365
50. M Grabacka PM Plonka K Urbanska 2006 Peroxisome proliferator-activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt Clin Cancer Res 12 3028 3036
51. H Shen AB Lentsch 2004 Progressive dysregulation of transcription factors NF-kappa B and STAT1 in prostate cancer cells causes proangiogenic production of CXC chemokines Am J Physiol Cell Physiol 286 C840 C847